Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 17
1966 25
1967 25
1968 22
1969 27
1970 25
1971 29
1972 21
1973 20
1974 18
1975 26
1976 31
1977 44
1978 37
1979 63
1980 48
1981 68
1982 72
1983 83
1984 92
1985 132
1986 121
1987 130
1988 121
1989 166
1990 179
1991 160
1992 200
1993 198
1994 208
1995 175
1996 192
1997 221
1998 203
1999 207
2000 216
2001 254
2002 267
2003 303
2004 285
2005 335
2006 389
2007 389
2008 369
2009 421
2010 427
2011 496
2012 497
2013 513
2014 562
2015 608
2016 609
2017 588
2018 585
2019 610
2020 778
2021 831
2022 931
2023 904
2024 352

Text availability

Article attribute

Article type

Publication date

Search Results

14,594 results

Results by year

Filters applied: . Clear all
Page 1
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC. Tew WP, et al. J Clin Oncol. 2020 Oct 20;38(30):3468-3493. doi: 10.1200/JCO.20.01924. Epub 2020 Aug 13. J Clin Oncol. 2020. PMID: 32790492 Free PMC article.
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Eur J Cancer. 2023 Aug;189:112908. doi: 10.1016/j.ejca.2023.04.024. Epub 2023 May 3. Eur J Cancer. 2023. PMID: 37263896 Free article. Clinical Trial.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Tewari KS, et al. J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19. J Clin Oncol. 2019. PMID: 31216226 Free PMC article. Clinical Trial.
Systemic therapy for non-serous ovarian carcinoma.
Chávarri-Guerra Y, González-Ochoa E, De-la-Mora-Molina H, Soto-Perez-de-Celis E. Chávarri-Guerra Y, et al. Chin Clin Oncol. 2020 Aug;9(4):52. doi: 10.21037/cco-20-36. Epub 2020 Jul 28. Chin Clin Oncol. 2020. PMID: 32787339 Free article. Review.
Maintenance therapy in ovarian cancer.
Khalique S, Hook JM, Ledermann JA. Khalique S, et al. Curr Opin Oncol. 2014 Sep;26(5):521-8. doi: 10.1097/CCO.0000000000000110. Curr Opin Oncol. 2014. PMID: 25033374 Review.
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Moore KN, et al. J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23. J Clin Oncol. 2021. PMID: 33891472 Free PMC article. Clinical Trial.
14,594 results
You have reached the last available page of results. Please see the User Guide for more information.